Literature DB >> 27514658

ESR1, ERBB2, and Ki67 mRNA expression predicts stage and grade of non-muscle-invasive bladder carcinoma (NMIBC).

Johannes Breyer1, Ralph M Wirtz2,3, Mark Laible4, Kornelia Schlombs4, Philipp Erben5, Maximilian Christian Kriegmair5, Robert Stoehr6, Sebastian Eidt3, Stefan Denzinger7, Maximilian Burger7, Arndt Hartmann6, Wolfgang Otto7.   

Abstract

Pathological staging and grading are crucial for risk assessment in non-muscle-invasive bladder cancer (NMIBC). Molecular grading might support pathological evaluation and minimize interobserver variability. In this study, the well-established breast cancer markers ESR1, PGR, ERBB2, and MKI67 were evaluated as potential molecular markers to support grading and staging in NMIBC. We retrospectively analyzed clinical data and formalin-fixed paraffin-embedded tissues (FFPE) of patients with NMIBC. Messenger RNA (mRNA) expression of the aforementioned markers was measured by single-step reverse transcription quantitative real-time polymerase chain reaction (RT-qPCR) using RNA-specific TaqMan assays. Relative gene expression was determined by normalization to two reference genes (CALM2 and B2M) using the 40-ΔΔCT method and correlated to histopathological stage and grade. Pathological assessment was performed by an experienced uropathologist. Statistical analysis was performed using the SAS software JMP 9.0.0 version and GraphPad Prism 5.04. Of 381 cases of NMIBC, samples of 100 pTa and 255 pT1 cases were included in the final study. Spearman rank correlation revealed significant correlations between grade and expression of MKI67 (r = 0.52, p < 0.0001), ESR1 (r = 0.25, p < 0.0001), and ERBB2 (r = 0.18, p = 0.0008). In Mann-Whitney tests, MKI67 was significantly different between all grades (p < 0.0001), while ESR1 (p = 0.0006) and ERBB2 (p = 0.027) were significantly different between G2 and G3. Higher expression of MKI67 (r = 0.49; p < 0.0001), ERBB2 (r = 0.22; p < 0.0001), and ESR1 (r = 0.18; p = 0.0009) mRNA was positively correlated with higher stage. MKI67 (p < 0.0001), ERBB2 (p = 0.0058), and PGR (p = 0.0007) were significantly different between pTa and pT1. In NMIBC expression of ESR1, ERBB2 and MKI67 are significantly different between stage and grade. This potentially provides objective parameters for pathological evaluation.

Entities:  

Keywords:  ERBB2; ESR1; Grade; MKI67; NMIBC; Stage

Mesh:

Substances:

Year:  2016        PMID: 27514658     DOI: 10.1007/s00428-016-2002-1

Source DB:  PubMed          Journal:  Virchows Arch        ISSN: 0945-6317            Impact factor:   4.064


  26 in total

Review 1.  EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder: update 2013.

Authors:  Marko Babjuk; Maximilian Burger; Richard Zigeuner; Shahrokh F Shariat; Bas W G van Rhijn; Eva Compérat; Richard J Sylvester; Eero Kaasinen; Andreas Böhle; Joan Palou Redorta; Morgan Rouprêt
Journal:  Eur Urol       Date:  2013-06-12       Impact factor: 20.096

Review 2.  The WHO classification of 1973 is more suitable than the WHO classification of 2004 for predicting survival in pT1 urothelial bladder cancer.

Authors:  Wolfgang Otto; Stefan Denzinger; Hans-Martin Fritsche; Maximilian Burger; Wolf F Wieland; Ferdinand Hofstädter; Arndt Hartmann; Simone Bertz
Journal:  BJU Int       Date:  2010-08-12       Impact factor: 5.588

3.  Prognostic factors in stage T1 grade 3 bladder cancer survival: the role of G1-S modulators (p53, p21Waf1, p27kip1, Cyclin D1, and Cyclin D3) and proliferation index (ki67-MIB1).

Authors:  A Lopez-Beltran; R J Luque; J Alvarez-Kindelan; A Quintero; F Merlo; J C Carrasco; M J Requena; R Montironi
Journal:  Eur Urol       Date:  2004-05       Impact factor: 20.096

4.  Overexpression of HER-2/neu oncogene and transitional cell carcinoma of bladder.

Authors:  Mohammad Reza Jalali Nadoushan; Touraj Taheri; Neda Jouian; Farid Zaeri
Journal:  Urol J       Date:  2007       Impact factor: 1.510

Review 5.  Role of oestrogen receptors in bladder cancer development.

Authors:  Iawen Hsu; Spencer Vitkus; Jun Da; Shuyuan Yeh
Journal:  Nat Rev Urol       Date:  2013-04-16       Impact factor: 14.432

6.  p53 and ki67 expression as prognostic factors for cancer-related survival in stage T1 transitional cell bladder carcinoma.

Authors:  Andrés Rodríguez-Alonso; Salvador Pita-Fernández; Joaquín González-Carreró; José Luis Nogueira-March
Journal:  Eur Urol       Date:  2002-02       Impact factor: 20.096

7.  Is quantitative real-time RT-PCR an adjunct to immunohistochemistry for the evaluation of ErbB2 status in transitional carcinoma of the bladder?

Authors:  Delphine Amsellem-Ouazana; Ivan Bièche; Vincent Molinié; Caroline Elie; Annick Vieillefond; Sengül Tozlu; Henry Botto; Bernard Debré; Rosette Lidereau
Journal:  Eur Urol       Date:  2006-01-30       Impact factor: 20.096

8.  Her2 amplification distinguishes a subset of non-muscle-invasive bladder cancers with a high risk of progression.

Authors:  Paul Chih-Hsueh Chen; Hui-Jung Yu; Yen-Hwa Chang; Chin-Chen Pan
Journal:  J Clin Pathol       Date:  2012-10-19       Impact factor: 3.411

9.  Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012.

Authors:  Jacques Ferlay; Isabelle Soerjomataram; Rajesh Dikshit; Sultan Eser; Colin Mathers; Marise Rebelo; Donald Maxwell Parkin; David Forman; Freddie Bray
Journal:  Int J Cancer       Date:  2014-10-09       Impact factor: 7.396

10.  Comprehensive molecular characterization of urothelial bladder carcinoma.

Authors: 
Journal:  Nature       Date:  2014-01-29       Impact factor: 49.962

View more
  17 in total

1.  Comprehensive Molecular Characterization of Muscle-Invasive Bladder Cancer.

Authors:  A Gordon Robertson; Jaegil Kim; Hikmat Al-Ahmadie; Joaquim Bellmunt; Guangwu Guo; Andrew D Cherniack; Toshinori Hinoue; Peter W Laird; Katherine A Hoadley; Rehan Akbani; Mauro A A Castro; Ewan A Gibb; Rupa S Kanchi; Dmitry A Gordenin; Sachet A Shukla; Francisco Sanchez-Vega; Donna E Hansel; Bogdan A Czerniak; Victor E Reuter; Xiaoping Su; Benilton de Sa Carvalho; Vinicius S Chagas; Karen L Mungall; Sara Sadeghi; Chandra Sekhar Pedamallu; Yiling Lu; Leszek J Klimczak; Jiexin Zhang; Caleb Choo; Akinyemi I Ojesina; Susan Bullman; Kristen M Leraas; Tara M Lichtenberg; Catherine J Wu; Nicholaus Schultz; Gad Getz; Matthew Meyerson; Gordon B Mills; David J McConkey; John N Weinstein; David J Kwiatkowski; Seth P Lerner
Journal:  Cell       Date:  2017-10-05       Impact factor: 41.582

2.  Role of downregulated miR-133a-3p expression in bladder cancer: a bioinformatics study.

Authors:  Li Gao; Sheng-Hua Li; Yi-Xin Tian; Qing-Qing Zhu; Gang Chen; Yu-Yan Pang; Xiao-Hua Hu
Journal:  Onco Targets Ther       Date:  2017-07-20       Impact factor: 4.147

3.  High Androgen Receptor mRNA Expression Is Independently Associated with Prolonged Cancer-Specific and Recurrence-Free Survival in Stage T1 Bladder Cancer.

Authors:  Danijel Sikic; Johannes Breyer; Arndt Hartmann; Maximilian Burger; Philipp Erben; Stefan Denzinger; Markus Eckstein; Robert Stöhr; Sven Wach; Bernd Wullich; Bastian Keck; Ralph M Wirtz; Wolfgang Otto
Journal:  Transl Oncol       Date:  2017-03-22       Impact factor: 4.243

4.  Enhancer RNA - P2RY2e induced by estrogen promotes malignant behaviors of bladder cancer.

Authors:  Mengting Ding; Hengji Zhan; Xinhui Liao; Aolin Li; Yucheng Zhong; Qunjun Gao; Yuchen Liu; Weiren Huang; Zhiming Cai
Journal:  Int J Biol Sci       Date:  2018-07-27       Impact factor: 6.580

5.  Comprehensive Analysis of Candidate Diagnostic and Prognostic Biomarkers Associated with Lung Adenocarcinoma.

Authors:  Jingyuan Li; Xingyuan Liu; Zan Cui; Guanying Han
Journal:  Med Sci Monit       Date:  2020-06-24

6.  Extracellular matrix protein 1 (ECM1) is associated with carcinogenesis potential of human bladder cancer.

Authors:  Zhicai Wang; Qun Zhou; Aolin Li; Weiren Huang; Zhiming Cai; Wei Chen
Journal:  Onco Targets Ther       Date:  2019-02-20       Impact factor: 4.147

7.  ANLN and TLE2 in Muscle Invasive Bladder Cancer: A Functional and Clinical Evaluation Based on In Silico and In Vitro Data.

Authors:  Sheng Wu; Katja Nitschke; Jakob Heinkele; Cleo-Aron Weis; Thomas Stefan Worst; Markus Eckstein; Stefan Porubsky; Philipp Erben
Journal:  Cancers (Basel)       Date:  2019-11-21       Impact factor: 6.639

8.  Androgen receptor expression and response to chemotherapy in breast cancer patients treated in the neoadjuvant TECHNO and PREPARE trial.

Authors:  Isabell Witzel; Sibylle Loibl; Ralph Wirtz; Peter A Fasching; Carsten Denkert; Karsten Weber; Hans-Joachim Lück; Jens Huober; Thomas Karn; Marion von Mackelenbergh; Frederik Marmé; Christian Schem; Elmar Stickeler; Michael Untch; Volkmar Müller
Journal:  Br J Cancer       Date:  2019-11-15       Impact factor: 7.640

9.  KRT20, KRT5, ESR1 and ERBB2 Expression Can Predict Pathologic Outcome in Patients Undergoing Neoadjuvant Chemotherapy and Radical Cystectomy for Muscle-Invasive Bladder Cancer.

Authors:  Hendrik Jütte; Moritz Reike; Ralph M Wirtz; Maximilian Kriegmair; Philipp Erben; Karl Tully; Veronika Weyerer; Markus Eckstein; Arndt Hartmann; Sebastian Eidt; Felix Wezel; Christian Bolenz; Andrea Tannapfel; Joachim Noldus; Florian Roghmann
Journal:  J Pers Med       Date:  2021-05-26

10.  Prognostic Value of Molecular Breast Cancer Subtypes based on Her2, ESR1, PGR and Ki67 mRNA-Expression in Muscle Invasive Bladder Cancer.

Authors:  M C Kriegmair; R M Wirtz; T S Worst; J Breyer; M Ritter; B Keck; C Boehmer; W Otto; M Eckstein; C A Weis; A Hartmann; C Bolenz; P Erben
Journal:  Transl Oncol       Date:  2018-02-23       Impact factor: 4.243

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.